A recent study examined the financial burden of cancer care on different patient populations, revealing varying average annual costs and prescription spending. Uninsured patients topped the list with an average annual cost of $78,439, followed by Medicare patients at $67,979. VA/TRICARE patients had moderate costs but higher prescription spending at $56,619 and $16,758, respectively. Medicaid […]
Category: Oncology
Verastem Oncology Stock Analysis
Investors are closely monitoring the performance of Verastem Oncology stock this Monday. Analysts are paying attention to various technical indicators, such as the 200-day moving average, to gauge the stock’s potential future trend. Currently, the stock price is above the 200-day moving average, indicating a bullish signal. To learn more about how technical analysis tools […]
Oncology Institute to be Added to Russell 2000 and Russell 3000 Indexes
Exciting news for the Oncology Institute as they are set to join the prestigious Russell 2000 and Russell 3000 Indexes. The annual reconstitution of the Russell indexes has identified the 4,000 largest US stocks as of April 30, ranking them based on total market capitalization. Membership in the US all-cap Russell 3000 Index guarantees automatic […]
AVEO Oncology Showcases Three Posters at ASCO 2025 Meeting
In a significant development at the ASCO 2025 Annual Meeting, AVEO Oncology, a subsidiary of LG Chem Life SciencesUSA, Inc., presented three posters highlighting their commitment to advancing oncology treatments. AVEO, known for its focus on delivering innovative medicines for cancer patients, currently offers FOTIVDA®(tivozanib) for advanced renal cell carcinoma treatment in the U.S. The […]
Fiber’s Impact on Immunotherapy in Cancer Treatment
0 Exciting research unveiled at the 2025 American Society of Clinical Oncology Annual Meeting reveals the potential of a fiber-rich, whole-foods-based diet in enhancing outcomes for patients undergoing immunotherapy for cancer, particularly in melanoma care. This innovative approach not only holds promise for improving patient results but also presents a cost-effective and widely applicable strategy, […]
Barriers to CAR T-Cell Therapy in Myeloma
Recent discussions among oncologists in West Virginia highlighted the challenges hindering the widespread use of Chimeric Antigen Receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma. Despite the therapy’s availability, social and logistical barriers prevent many eligible patients from accessing this innovative treatment option. Dr. Konstantinos Sdrimas, an expert in medical oncology, emphasized the […]
The Tumor Microenvironment: Why the Real Action Happens off-Screen
1 A quick scene-setter (coffee optional) Cancer biologists like to call the tumor a “mass.” In reality it behaves more like Times Square on New Year’s Eve: a jostling crowd of tourists (immune cells), cops (fibroblasts), food trucks (blood vessels), pickpockets (cancer-associated macrophages) and the giant LED billboards of cytokines blaring contradictory instructions. That carnival […]
